Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of ModraDoc006/r in recurrent or metastatic HER2-negative breast cancer
2018-003249-41Phase 2Completed
- Sponsor
- Modra Pharmaceuticals
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ModraDoc006 and ritonavir in breast cancer, sponsored by Modra Pharmaceuticals. Primary endpoint: Objective response rate. Started Sep 2018; status: completed.
02
Drugs
ModraDoc006ritonavir
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-003249-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003249-41.